Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model [PDF]
NOTICE: this is the author’s version of a work that was accepted for publication in Neurobiology of Disease. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control ...
Ezzatizadeh, V +17 more
core +1 more source
HDACs and HDAC inhibitors in colon cancer [PDF]
The histone deacetylase (HDAC) family of transcriptional co-repressors have emerged as important regulators of colon cell maturation and transformation. Pharmacological inhibitors of class I and II HDAC activity (HDACi) are potent inducers of growth arrest, differentiation and apoptosis of colon cancer cells in vitro and in vivo, implicating a role for
openaire +2 more sources
Dual Inhibitors Targeting DNA and Histone Deacetylases
Histone deacetylases (HDACs) regulate the acetylation status of histones and structural status of chromatin. The chromatin structure becomes relaxed after inhibition of HDAC, leading to DNA exposed to DNA disrupting agents, and eventually causing DNA ...
Chen Chen +3 more
doaj +1 more source
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases [PDF]
Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states.
Yoon, Somy, Eom, Gwang Hyeon
openaire +2 more sources
Teorijsko proučavanje interakcija između HDAC-1 i HDAC-6 enzima i in silico dizajniranih inhibitora [PDF]
The disproportionate posttranslational histone modification as deacetylation has been associated with tumorigenesis and neurodegenerative diseases. Currently, there are five approved histone deacetylase (HDAC) inhibitors by FDA, which are defined as pan ...
Ružić, Dušan +2 more
core +4 more sources
Identification of Novel 4-Oxo-4H-chromen-Hydroxamic Acid Derivative Targeting Selected HDAC Isoforms
Histone deacetylase inhibitors (HDACIs) represent a well-known class of compounds that exhibit potential therapeutic efficacy in a variety of diseases, particularly cancer and neurodegenerative disorders.
Rosaline Ashraf +3 more
doaj +1 more source
Human EGFR-2, EGFR and HDAC triple-inhibitor CUDC-101 enhances radiosensitivity of GBM cells
Radiotherapy remains the standard treatment for glioblastoma multiforme (GBM) following surgical resection. Given the aberrant expression of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) which may play a role
Cody D Schlaff +4 more
doaj +1 more source
Ring size changes in the development of class I HDAC inhibitors
Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over
Er-Chieh Cho +3 more
doaj +1 more source
Table S1. Hybrid RTK/HDAC inhibitors (1-19) developed in the last years. Table S2. Hybrid non-receptor TK/HDAC inhibitors 20 28) developed in the last years. Table S3. Hybrid SK/HDAC inhibitors (29-39) developed in the last years.
Karoline B. Waitman (10351881) +1 more
core +1 more source
HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents [PDF]
The NRF2 signalling cascade provides a primary response against electrophilic chemicals and oxidative stress. The activation of NRF2-signaling is anticipated to have adverse clinical consequences; NRF2 is activated in a number of cancers, additionally ...
A Kenneth MacLeod +17 more
core +2 more sources

